bluebird bio set to reveal immune-oncology and gene therapy data

In News by

bluebird bio, Inc., have announced that they will holding a total of 10 presentations at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, being held on the 4th-7th May in Washington, D.C. They are set to present data from their clinical, preclinical, and research and manufacturing programs.

The academic collaborators of bluebird will give two of the presentation and will highlight data that has been previously presented from bluebird’s ongoing clinical trials. Interim data from the Phase 2/3 Starbeam Study of their candidate gene therapy, using a lentiviral (Lenti-D) vector to treat cerebral adrenoleukodystrophy, will be presented by David Williams, MD, chief of hematology/oncology at Boston Children’s Hospital. Marina Cavazzana, MD, PhD, of Hospital Necker, University Paris Descartes, will be presenting data from the HGB-205 study of LentiGlobin in patients with severe sickle cell disease and those with transfusion-dependent β-thalassemia.

“As bluebird continues to build a differentiated T cell oncology franchise, we are excited to present three oncology abstracts that highlight our work on the next generation of technology for T cell-based immunotherapy – including methods of generating T cells with sustained anti-tumor activity, small-molecule regulated chimeric antigen receptors (CARs) and genome editing to generate improved CAR T cells. From our hematopoietic stem cell programs, we will also share updates in five presentations covering improvements in scalable manufacturing, transduction efficiency and assay development – critical areas for making gene therapy available to more patients.” – Philip Gregory, CSO at bluebird bio.

Source: bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting; Press Release